LEADER 01981nam  2200349z- 450 
001 9910671107803321
005 20180410221905.0
035   $a(CKB)5470000001388918
035   $a(EXLCZ)995470000001388918
100   $a20220406c2016uuuu  -u-            -
101 0 $aeng
200 00$aANDA litigation $estrategies and tactics for pharmaceutical patent litigators /$fKenneth L. Dorsney, editor-in-chief
210   $cAmerican Bar Association
311   $a1-63425-458-9 
327   $aThe statutory and regulatory scheme -- The drug approval process--an overview -- Notice and prefiling considerations -- The litigation timeline -- Initiating litigation -- Use of reissue proceedings in Hatch-Waxman litigation -- Inter partes review in ANDA litigation -- Examining subject-matter jurisdiction over declaratory judgment claims filed in combination with patent infringement claims under section 271(e)(2)(a) -- Responding to the complaint -- Discovery -- Experts -- Claim construction -- Summary judgment -- Remedies -- Settlement -- Antitrust -- Pretrial preparation -- Trial -- Posttrial -- Appeals to the Court of Appeals for the Federal Circuit -- Hatch-Waxman practice in the Supreme Court of the United States -- Managing an ANDA litigation -- Pharmaceutical regulation and litigation in foreign countries.
517   $aANDA litigation
606   $aBiotechnology$zUnited States$xPatents
606   $aDrugs$zUnited States$xPatents
606   $aPatent suits$zUnited States
606   $aPharmacy$xLaw and legislation$zUnited States
610   $aAbbreviated New Drug Application.
615  0$aBiotechnology$xPatents.
615  0$aDrugs$xPatents.
615  0$aPatent suits
615  0$aPharmacy$xLaw and legislation
676   $a346.7304/86
702   $aDorsney$b Kenneth L.
712 02$aAmerican Bar Association.$bSection of Intellectual Property Law,
906   $aBOOK
912   $a9910671107803321
996   $aANDA litigation$93049757
997   $aUNINA